Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 145 stocks over the last week. The average A-H premium was 111.5% as of Jul 26th.</li>
<li>The average A-H premium changed by 3.6ppt week-on-week, led by utilities, information technology, financials and offset by consumer staples, communication services.</li>
<li>We highlight weekly changes in A-H premium for Asymchem Labor, Livzon Pharm, Shanghai Pharm, Pharmaron Beij, Hua Hong Semi, CICC.</li>
</ul>


We analyse the changes of A-H premium on 145 stocks over the last week. The average A-H premium was 111.5% as of Jul 26th.
The average A-H premium changed by 3.6ppt week-on-week, led by utilities, information technology, financials and offset by consumer staples, communication services.
We highlight weekly changes in A-H premium for Asymchem Labor, Livzon Pharm, Shanghai Pharm, Pharmaron Beij, Hua Hong Semi, CICC.


A-H Premium Weekly (Jul 26th):Asymchem, Livzon Pharm, Shanghai Pharm, Pharmaron

<ul>
<li>We analyse the changes of A-H premium on 146 stocks over the last week. The average A-H premium was 107.8% as of Jul 19th.</li>
<li>The average A-H premium changed by 2.0ppt week-on-week, led by communication services, energy, utilities and offset by consumer staples, information technology, real estate.</li>
<li>We highlight weekly changes in A-H premium for Wuapptec, Air China, China Longyuan, Smic, Yofc, Flat Glass, Ganfeng Lithium.</li>
</ul>


We analyse the changes of A-H premium on 146 stocks over the last week. The average A-H premium was 107.8% as of Jul 19th.
The average A-H premium changed by 2.0ppt week-on-week, led by communication services, energy, utilities and offset by consumer staples, information technology, real estate.
We highlight weekly changes in A-H premium for Wuapptec, Air China, China Longyuan, Smic, Yofc, Flat Glass, Ganfeng Lithium.


A-H Premium Weekly (Jul 19th):Wuxi Apptec, Air China, China Longyuan, Smic, Yofc, Flat Glass

Pan-Asia Index Flows & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Pan-Asia Index Flows & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

Beijing-Shanghai High Speed Ra / Event-Driven

<ul>
<li>SSE 50 and SSE 180, respectively, aim to represent the performance of the 50 and 180 largest and most liquid A-share stocks listed on the Shanghai Stock Exchange.</li>
<li>In this insight, we take a look at the names leading the race to become ADDs and DELs during the December 2024 index rebal event.</li>
<li>There have been some changes to the SSE 180 expected ADDs/DELs lists since our last insight.</li>
</ul>


SSE 50 and SSE 180, respectively, aim to represent the performance of the 50 and 180 largest and most liquid A-share stocks listed on the Shanghai Stock Exchange.
In this insight, we take a look at the names leading the race to become ADDs and DELs during the December 2024 index rebal event.
There have been some changes to the SSE 180 expected ADDs/DELs lists since our last insight.


Quiddity Leaderboard SSE50/180 Dec 24: US$1.6bn+ One-Way; Some Changes to Expectations.

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>Retail pharmacies experienced performance decline in April and May. Due to negative policies, retail pharmacies will experience industry clearance. Therefore, we do not recommend investors to bottom-fish related stocks now.</li>
<li>There is a logic to biotech's performance from 2023 to present.The clearer the path of sustainable development, the better the stock price performance. They can be divided into three types.</li>
<li>YSB faces big risks and the outlook is not optimistic. If the final valuation of the Company is lower than <a href="https://www.smartkarma.com/entities/china-resources-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:22928:1" rel="noopener">China Resources Pharmaceutical</a> and <a href="https://www.smartkarma.com/entities/shanghai-pharmaceuticals-holding" target="_blank" data-smartkarma-citation="entities:228:1" rel="noopener">Shanghai Pharmaceuticals</a>, we wouldn't be too surprised.</li>
</ul>


Retail pharmacies experienced performance decline in April and May. Due to negative policies, retail pharmacies will experience industry clearance. Therefore, we do not recommend investors to bottom-fish related stocks now.
There is a logic to biotech's performance from 2023 to present.The clearer the path of sustainable development, the better the stock price performance. They can be divided into three types.
YSB faces big risks and the outlook is not optimistic. If the final valuation of the Company is lower than China Resources Pharmaceutical and Shanghai Pharmaceuticals, we wouldn't be too surprised.


China Healthcare Weekly (Jun23)-Retail Pharmacy's Dilemma, Logic to Biotech's Stock Price,YSB's Risk

China Resources Pharmaceutical / Equity Bottom-Up

<ul>
<li>The NHSA issued a Notice on “improving the quality and expanding the scope of VBP”. The trend of full coverage of VBP of conventional drugs/consumables is determined.TCM is under pressure.</li>
<li>We analyzed the potential demand growth rate of the glove industry, which is already better than most cyclical stocks. Therefore, we see no need to remain pessimistic about this industry.</li>
<li>Holding platform companies have valuation discounts.HK$50-60 billion is reasonable market value for China Resources Pharmaceutical.Better to go long when share price is below HK$5 and then hold to receive dividends.</li>
</ul>


The NHSA issued a Notice on “improving the quality and expanding the scope of VBP”. The trend of full coverage of VBP of conventional drugs/consumables is determined.TCM is under pressure.
We analyzed the potential demand growth rate of the glove industry, which is already better than most cyclical stocks. Therefore, we see no need to remain pessimistic about this industry.
Holding platform companies have valuation discounts.HK$50-60 billion is reasonable market value for China Resources Pharmaceutical.Better to go long when share price is below HK$5 and then hold to receive dividends.


China Healthcare Weekly (May.26)-VBP Scope Expands, Optimistic About Glove Industry, China Resources

China

Shanghai Pharmaceuticals Holding Co., Ltd manufactures pharmaceuticals. The Company develops and sells chemical and Chinese traditional medicines, healthcare products, and other products. Shanghai Pharmaceuticals Holding markets its products throughout China.

Shanghai Pharmaceuticals Holding (601607 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Pharmaceuticals Holding (601607 CH)

A-H Premium Weekly (Jul 26th):Asymchem, Livzon Pharm, Shanghai Pharm, Pharmaron

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Asymchem Labor, Livzon Pharm, Shanghai Pharm, Pharmaron...

Ke Yan, CFA, FRM

A-H Premium Weekly (Jul 19th):Wuxi Apptec, Air China, China Longyuan, Smic, Yofc, Flat Glass

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Wuapptec, Air China, China Longyuan, Smic, Yofc, Flat Glass,...

Ke Yan, CFA, FRM

Quiddity Leaderboard SSE50/180 Dec 24: US$1.6bn+ One-Way; Some Changes to Expectations.

There could be US$1.4bn and US$240mn one-way flows, respectively, for the SSE 50 and SSE 180 December 2024 rebalances. Around 70% of the reference...

Janaghan Jeyakumar, CFA

China Healthcare Weekly (Jun23)-Retail Pharmacy's Dilemma, Logic to Biotech's Stock Price,YSB's Risk

Retail pharmacies facing industry clearance due to negative policies.Biotech stock performance tied to sustainable development path. YSB faces...

Xinyao (Criss) Wang

China Healthcare Weekly (May.26)-VBP Scope Expands, Optimistic About Glove Industry, China Resources

Due to VBP scope expansion, TCM will face more pressure.Time to be optimistic about glove industry, which is better than expected.China Resources...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

A-H Premium Weekly (Jul 26th):Asymchem, Livzon Pharm, Shanghai Pharm, Pharmaron

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Asymchem Labor, Livzon Pharm, Shanghai Pharm, Pharmaron...

Ke Yan, CFA, FRM

A-H Premium Weekly (Jul 19th):Wuxi Apptec, Air China, China Longyuan, Smic, Yofc, Flat Glass

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Wuapptec, Air China, China Longyuan, Smic, Yofc, Flat Glass,...

Ke Yan, CFA, FRM

Quiddity Leaderboard SSE50/180 Dec 24: US$1.6bn+ One-Way; Some Changes to Expectations.

There could be US$1.4bn and US$240mn one-way flows, respectively, for the SSE 50 and SSE 180 December 2024 rebalances. Around 70% of the reference...

Janaghan Jeyakumar, CFA

China Healthcare Weekly (Jun23)-Retail Pharmacy's Dilemma, Logic to Biotech's Stock Price,YSB's Risk

​Retail pharmacies facing industry clearance due to negative policies.Biotech stock performance tied to sustainable development path. YSB faces...

Xinyao (Criss) Wang

China Healthcare Weekly (May.26)-VBP Scope Expands, Optimistic About Glove Industry, China Resources

Due to VBP scope expansion, TCM will face more pressure.Time to be optimistic about glove industry, which is better than expected.China Resources...

Xinyao (Criss) Wang

Retail pharmacies facing industry clearance due to negative policies.Biotech stock performance tied to sustainable development path. YSB faces...